Re: First Procedure performed in U.S. trial for SpraGel-from obgyn.net. - for Dr. Moore

From: Kathi (kredfield@juno.com)
Fri Jan 10 10:23:01 2003

At Fri, 10 Jan 2003, clareS wrote: >
>I found this on the obgyn.net news site.
>Clare
>
>First procedure performed in U.S. trial for SprayGel Adhesion Barrier
>Adhesions
>August 1, 2002
>2002 AUG 1 - (NewsRx.com & NewsRx.net) -- Confluent Surgical, Inc.,
>announced the commencement of its pivotal U.S. trial for the SprayGel
>Adhesion Barrier in Prevention of Pelvic Adhesions In Laparoscopic
>Surgery, the PREVAIL Study. Confluent Surgical believes that the
>SprayGel Adhesion Barrier will prevent and reduce adhesions that are
>associated with severe postoperative pain and other side effects, which
>affect millions of women annually.
>
>The first procedure in the PREVAIL Study was performed by Michael L.
>Twede, MD, FACOG, and Dale A. Sundwall, MD, FACOG, Medical Directors at
>the Salt Lake City Women's Center. Twede and Sundwall are considered
>experts in the treatment of endometriosis and adhesions and are
>respected as highly skilled surgeons.
>
>Twede states, "Based on the early published results, SprayGel appears to
>represent a breakthrough in adhesion prevention. It is unique in its
>ability to be applied laparoscopically and remain in place as a barrier
>for five to seven days, the period when adhesions normally form. If the
>results from the initial pilot study are replicated in this pivotal
>study, this product would prevent or significantly reduce patient trauma
>and costs associated with additional surgery for adhesions."
>
>Adhesions are fibrous bands of tissue between adjacent organs of the
>body. They typically occur as a result of inflammation incident to
>surgery and can cause severe pelvic pain and infertility. Adhesions
>start to form within three hours of surgery and will cease forming when
>the surgical sites heal, usually within 7 days following surgery. The
>SprayGel Adhesion Barrier is designed to protect the tissues during this
>critical healing period. It is estimated that adhesions affect over two
>million women and men in the U.S. and that the potential U.S. market
>for abdominopelvic adhesion management is $400-$500 million.
>
>"Based on its early performance in prior pilot trials as well as our
>early commercial success in Europe, we believe that SprayGel will become
>the product of choice for gynecologic surgeons to prevent postoperative
>adhesions," stated Amar S. Sawhney, president and CEO of Confluent
>Surgical, Inc. This article was prepared by Women's Health Weekly
>editors from staff and other reports.
>
>©Copyright 2002, Women's Health Weekly via NewsRx.com & NewsRx.net
>
>Click here for additional articles on Preventive Medicine
>
> return to OBGYN.net Headline News ... (2001 archives)

--
How can one get into these clinical trials?

Enter keywords:
Returns per screen: Require all keywords: